Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee
Status: | Completed |
---|---|
Conditions: | Arthritis, Osteoarthritis (OA) |
Therapuetic Areas: | Rheumatology |
Healthy: | No |
Age Range: | 40 - Any |
Updated: | 1/14/2018 |
Start Date: | November 2013 |
End Date: | April 2014 |
An Open-label, Single Administration Study to Characterize the Local Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis (OA) of the Knee
The purpose of this study was to characterize the local duration of exposure of TCA for 2
doses of FX006 relative to 40 mg of TCA IR in patients with OA of the knee.
doses of FX006 relative to 40 mg of TCA IR in patients with OA of the knee.
This study was an open-label, single administration design, conducted in male and female
patients ≥40 years of age with OA of the knee.
Patients were enrolled sequentially with 8 patients per cohort, as follows:
Cohort A: FX006 40 mg, Final Visit at Week 20 Cohort B: FX006 40 mg, Final Visit at Week 16
Cohort C: FX006 10 mg, Final Visit at Week 12 Cohort D: FX006 40 mg, Final Visit at Week 12
Cohort E: Triamcinolone acetonide immediate-release (TCA IR) 40 mg, Final Visit Week 12
Each patient was evaluated for up to 12, 16, or 20 weeks following a single IA injection
depending on the assigned cohort. Following the screening visit, safety was evaluated at 3
out-patient visits and synovial fluid was collected at Day 1 for baseline measurements and
the Final Visit for drug concentration measurements.
patients ≥40 years of age with OA of the knee.
Patients were enrolled sequentially with 8 patients per cohort, as follows:
Cohort A: FX006 40 mg, Final Visit at Week 20 Cohort B: FX006 40 mg, Final Visit at Week 16
Cohort C: FX006 10 mg, Final Visit at Week 12 Cohort D: FX006 40 mg, Final Visit at Week 12
Cohort E: Triamcinolone acetonide immediate-release (TCA IR) 40 mg, Final Visit Week 12
Each patient was evaluated for up to 12, 16, or 20 weeks following a single IA injection
depending on the assigned cohort. Following the screening visit, safety was evaluated at 3
out-patient visits and synovial fluid was collected at Day 1 for baseline measurements and
the Final Visit for drug concentration measurements.
Key Inclusion Criteria:
- Written consent to participate in the study
- Willingness and ability to comply with the study procedures and visit schedules and
ability to follow verbal and written instructions
- Has documented diagnosis of OA of the index knee made at least 6 months prior to
Screening
- Currently meets American Collage of Rheumatology Criteria (clinical and radiological)
for OA
- Index knee pain for >15 days over the last month
- Body mass index (BMI) ≤ 40 kg/m2
- Ambulatory and in good general health
Key Exclusion Criteria:
- History of Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing
spondylitis, arthritis associated with inflammatory bowel disease, sarcoidosis or
amyloidosis
- History of arthritides due to crystals (e.g., gout, pseudogout)
- History of infection in the index joint
- Clinical signs and symptoms of active knee infection or crystal disease of the index
knee
- Presence of surgical hardware or other foreign body in the index knee
- Unstable joint (such as a torn anterior cruciate ligament) within 12 months of
Screening
- IA corticosteroid (investigational or marketed) in any joint within 6 months of
Screening
- IA hyaluronic acid (investigational or marketed) in the index knee within 6 months of
Screening
- Oral corticosteroids (investigational or marketed) within 1 month of Screening
- Inhaled, intranasal and topical corticosteroids (investigational or marketed) within 2
weeks of Screening
- Any other IA investigational drug/biologic within 6 months of Screening
- Prior use of FX006
- Prior arthroscopic or open surgery of the index knee within 12 months of Screening
- Planned/anticipated surgery of the index knee during the study period
- Active or history of malignancy within the last 5 years, with the exception of
resected basal cell carcinoma, squamous cell carcinoma of the skin, or resected
cervical atypia or carcinoma in situ
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials